History
In 1977, Ethypharm started its business in low-key fashion – at the same time the company had precisely ten employees. The new start up soon proved a success, with marketing authorisations and new product launches coming thick and fast. The company quickly realised that future success lay in exports and promptly headed out to look for new markets: among them, China, India and North America.
30 years on (and 50 development products later), Ethypharm has hoisted itself up to rank among the world’s leaders in the DDS market.
Today, the company numbers 800 employees worldwide.
Creation of Ethypharm in Trappes (near Paris) inside Roger Logeais pharmaceutical laboratory. At the start, the company employs about 10 employees.
Launch of Vincamine "Tripervan ®".
Launch of ISDN (Langoran ®) with Merrell laboratories (Sanofi Aventis).
Launch of Armophyline, the first oral modified release formulation of theophylin marketed in France.
Launch of Fenofibrate and Doxycicline. Initiation of the first contacts with Brazil through the creation of a production unit in Rio de Janeiro inside the Knoll (Abott) site of production.
Start of the Spanish subsidiary and launch of Fenofibrate on the Spanish market.
Launch of ISMN with Pierre Fabre under the brandname Monicor ®.
Creation of a joint venture in Turky with Nobel laboratories.
Firt contacts for Ethypharm with China.
Launch of Diltiazem with Houdé laboratory (Roussel-Uclaf group).
Moving in Ethypharm's headquaters and General Management to Saint-Cloud, near western suburb of Paris.
Launch of Morphine Sulfate twice a day with UPSA (BMS). Marketing authorizations in more than 50 countries. The product is marketed by more than 20 partners, which sets Ethypharm number one in Europe with 26% market shares.
1 billion doses each year corresponding to 300 different references.
Ethypharm officially opens its production site in Shanghai. It is the first pharmaceutical company to create a joint venture and enter the Chinese market.
Launch of Ibuprofen with "Nureflex" in collaboration with Boots.
Buy-out of Lloyds, an Indian pharmaceutical company.
Fitting out and start of the factory located in Grand Quevilly (suburb of Rouen, France) specialized in the manufacture of high added value products.
Buy-out of Lloyds, an Indian pharmaceutical company.
Fitting out and start of the factory located in Grand Quevilly (suburb of Rouen, France) specialized in the manufacture of high added value products.
Setting up in North America with the buy-out of a Research and Development center in Laval (Suburb of Montreal, Canada).
Buy-out of Prographarm, Ethypharm's single French competitor, enabling the company to raise among the top ten worldwide leaders in the field of Drug Delivery Systems.
Buy-out of Prographarm, Ethypharm's single French competitor, enabling the company to raise among the top ten worldwide leaders in the field of Drug Delivery Systems.
Ethypharm awarded "Economic Growth Champion 2001", by l'Usine Nouvelle, a famous French economic and industrial newspaper, for the Energy-Chemestry-Pharmacy-Cosmeticc area.
First Ethypharm's product launched on the Japonese market with its oral modified release Morphine Sulfate.
Gérard Leduc is appointed President and General Manager.
Launch of Buprenorphine in France with Arrow Generics.
Astorg partners lead MBO of Ethypharm alongside management and existing investors.
Ethypharm in Philadelphia. The DDS Group confirms its implantation on the American Market.
